EUCTR2008-001609-40-DK进行中（未招募）不适用
An 8-week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,611
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female outpatients 18 years of age or older.
- •2. Patients must have a msDBP = 90 mmHg and < 110 mmHg at the visit prior to Visit 3 (Visit 2 or optional Visit 201).
- •3. Patients must have a msDBP = 95 mmHg and < 110 mmHg at Visit 3 (Day 1 /
- •randomization).
- •4. All patients must have an absolute difference of = 10 mmHg in their msDBP during the last 2 visits of the single-blind run-in period (Visit 2 and 3 or Visits 201 and 3).
- •5. Patients who are eligible and able to participate in the study, and who consent to do so after the purpose and nature of the investigation has been clearly explained to them (written informed consent).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years)
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •For full list, please refer to the protocol.
- •1. Patients previously treated in an aliskiren study that contained the treatment group of the combination of aliskiren and amlodipine and had been randomized or enrolled into the active drug treatment period of that study.
- •2. Severe hypertension (msDBP =110 mmHg and/or msSBP = 180 mmHg).
- •3. Pregnant or nursing (lactating) women, where pregnancy is defined as a state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (= 5 mIU/ml).
- •4. Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they are using two birth control methods. The two methods can be a double barrier method (if accepted by local ethnics committee) or a barrier method plus a hormonal method.
- •Adequate barrier methods of contraception include: diaphragm, condom (by the
- •partner), intrauterine device (copper or hormonal), sponge or spermicide. Hormonal contraceptives include any marketed contraceptive agent that includes an estrogen and/or a progestational agent.
- •Reliable contraception should be maintained throughout the study and for 7 days after the study.
- •Woman are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum FSH levels > 40 mIU/ml [for US only: and estradiol <20 pg/ml] or have had surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
- •5. History or evidence of a secondary form of hypertension.
- •6. Known Keith-Wagener grade III or IV hypertensive retinopathy.
- •7. Any history of hypertensive encephalopathy or cerebrovascular accident, or history of transient ischemic attack (TIA), myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention (PCI).
- •8. Previous or current diagnosis of heart failure (NYHA Class II-IV).
- •9. Serum potassium = 5.3 mEq/L (mmol/L) at Visit 1.
- •10. Patients with Type 1 or Type 2 diabetes mellitus who are not well controlled based on the investigator's clinical judgment. It is recommended that patients currently being treated for diabetes mellitus be on stable dose of antidiabetic medication for at least 4 weeks prior to Visit 1.
- •11. Current angina pectoris requiring pharmacological therapy (use of nitrates for the treatment of angina will be allowed).
- •12. Second or third degree heart block without a pacemaker, or potentially life-threatening arrhythmia during the 12 months prior to Visit 1.
- •13. Clinically symptomatic valvular heart disease at Visit 1.
研究者
相似试验
进行中（未招募）
不适用
An 8-week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension.hypertensionEUCTR2008-001609-40-GRovartis Pharma Services AG1,611
进行中（未招募）
不适用
An 8-week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension.MedDRA version: 9.1Level: LLTClassification code 10020772Term: HypertensionhypertensionEUCTR2008-001609-40-FIovartis Pharma Services AG1,611
进行中（未招募）
不适用
An 8-week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension.hypertensionEUCTR2008-001609-40-SEovartis Pharma Services AG1,611
进行中（未招募）
1 期
An 8-week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertensioEUCTR2004-000240-25-FIovartis Finland OY
进行中（未招募）
不适用
An 8 week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patiens with essential hypertensioEUCTR2004-000240-25-SEovartis Sverige AB2,685